Similar articles for PMID: 22347803

Year	Number of Results
2003	1
2005	1
2006	2
2007	1
2008	1
2009	1
2010	10
2011	6
2012	10
2013	6
2014	8
2015	7
2016	8
2017	6
2018	7
2019	8
2020	8
2021	1
2022	1
2024	0

1

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer.

Vergnenègre A, Ray JA, Chouaid C, Grossi F, Bischoff HG, Heigener DF, Walzer S. Vergnenègre A, et al. Clinicoecon Outcomes Res. 2012;4:31-7. doi: 10.2147/CEOR.S25923. Epub 2012 Jan 26. Clinicoecon Outcomes Res. 2012. PMID: 22347803 Free PMC article.

2

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe.

Walleser S, Ray J, Bischoff H, Vergnenègre A, Rosery H, Chouaid C, Heigener D, de Castro Carpeño J, Tiseo M, Walzer S. Walleser S, et al. Clinicoecon Outcomes Res. 2012;4:269-75. doi: 10.2147/CEOR.S31794. Epub 2012 Sep 14. Clinicoecon Outcomes Res. 2012. PMID: 23028234 Free PMC article.

3

Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.

Medical Advisory Secretariat. Medical Advisory Secretariat. Ont Health Technol Assess Ser. 2010;10(24):1-48. Epub 2010 Dec 1. Ont Health Technol Assess Ser. 2010. PMID: 23074402 Free PMC article.

4

Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.

Greenhalgh J, Bagust A, Boland A, Dwan K, Beale S, Hockenhull J, Proudlove C, Dundar Y, Richardson M, Dickson R, Mullard A, Marshall E. Greenhalgh J, et al. Health Technol Assess. 2015 Jun;19(47):1-134. doi: 10.3310/hta19470. Health Technol Assess. 2015. PMID: 26134145 Free PMC article. Review.

5

A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.

Nuijten MJ, de Castro Carpeño J, Chouaid C, Vergnenègre A, Grossi F, Bischoff H, Heigener D, Walzer S. Nuijten MJ, et al. Lung Cancer. 2012 Jun;76(3):465-71. doi: 10.1016/j.lungcan.2011.11.005. Epub 2011 Dec 5. Lung Cancer. 2012. PMID: 22153602

6

Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.

Dickson R, Bagust A, Boland A, Blundell M, Davis H, Dundar Y, Hockenhull J, Martin Saborido C, Oyee J, Ramani VS. Dickson R, et al. Pharmacoeconomics. 2011 Dec;29(12):1051-62. doi: 10.2165/11591600-000000000-00000. Pharmacoeconomics. 2011. PMID: 21967156 Clinical Trial.

7

Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC).

Faehling M, Achenbach J, Staib P, Steffen U, Tessen HW, Gaillard VE, Brugger W. Faehling M, et al. J Cancer Res Clin Oncol. 2018 Jul;144(7):1375-1383. doi: 10.1007/s00432-018-2649-x. Epub 2018 Apr 23. J Cancer Res Clin Oncol. 2018. PMID: 29687154 Clinical Trial.

8

Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer.

Juhász E, Kim JH, Klingelschmitt G, Walzer S. Juhász E, et al. Eur J Cancer. 2013 Apr;49(6):1205-15. doi: 10.1016/j.ejca.2012.11.006. Epub 2013 Mar 7. Eur J Cancer. 2013. PMID: 23477998 Clinical Trial.

9

Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France.

Pignata M, Chouaid C, Le Lay K, Luciani L, McConnachie C, Gordon J, Roze S. Pignata M, et al. Clinicoecon Outcomes Res. 2017 Oct 25;9:655-668. doi: 10.2147/CEOR.S136657. eCollection 2017. Clinicoecon Outcomes Res. 2017. PMID: 29123418 Free PMC article.

10

Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.

Vergnenegre A, Massuti B, de Marinis F, Carcereny E, Felip E, Do P, Sanchez JM, Paz-Arez L, Chouaid C, Rosell R; Spanish Lung Cancer Group, Italian Association of Thoracic Oncology, and French Lung Cancer Group. Vergnenegre A, et al. J Thorac Oncol. 2016 Jun;11(6):801-7. doi: 10.1016/j.jtho.2016.02.004. Epub 2016 Feb 18. J Thorac Oncol. 2016. PMID: 26899757 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

84 results

Results by year